InsiderTrades.com logo
Hottest Stock Pick for 2021
From Emerging Markets Consulting   |   Ad
This could be the most underrated stock available. Watch it closely.
Click here to learn more

NYR Insider Trading (Nyrada)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$8,925.00
Insider Selling (Last 12 Months): A$0.00

Nyrada Insider Trading History Chart

This chart shows the insider buying and selling history at Nyrada by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nyrada Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for NYR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Hottest Stock Pick for 2021
From Emerging Markets Consulting   |   Ad
This could be the most underrated stock available. Watch it closely.
Click here to learn more

Nyrada Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/29/2021Ruediger WeselohInsiderIssued100,000A$0.26A$26,000.00
2/23/2021Marcus FramptonInsiderBuy25,000A$0.36A$8,925.00
9/10/2020John MooreInsiderBuy32,500A$0.21A$6,825.00
4/23/2020John MooreInsiderBuy35,000A$0.17A$5,880.00
See Full Table
Insider Buying at Nyrada?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Nyrada and related companies.

SEC Filings (Institutional Ownership Changes) for Nyrada (ASX:NYR)

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in the drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. The company is also developing NYR-BI01 to treat traumatic brain injury and stroke. Nyrada Inc. has collaboration with Walter Reed Army Institute of Research and UNSW. The company was incorporated in 2017 and is based in Gordon, Australia.
Read More on Nyrada

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

65,000 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Nyrada?

Nyrada's top insider investors include:
  1. John Moore (Insider)
  2. Marcus Frampton (Insider)
  3. Ruediger Weseloh (Insider)
Hottest Stock Pick for 2021
From Emerging Markets Consulting   |   Ad
This could be the most underrated stock available. Watch it closely.
Click here to learn more